Similarly, octreotide-treatment also reduced phosphorylation levels of key intermediates in the NF-κB pathway (i.e., ZAP70/TAK1), whose activation has been linked to GBM-growth/invasion [83–85]. This evidence concerns the gene NFKB1 and glioblastoma.